Agle 102 (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
36 | Epidermolysis bullosa | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04173650 (ClinicalTrials.gov) | September 2020 | 18/11/2019 | MSC EVs in Dystrophic Epidermolysis Bullosa | A Safety Study of the Administration of MSC Extracellular Vesicles in the Treatment of Dystrophic Epidermolysis Bullosa Wounds | Dystrophic Epidermolysis Bullosa | Drug: AGLE 102 | Aegle Therapeutics | NULL | Not yet recruiting | N/A | N/A | All | 10 | Phase 1;Phase 2 | NULL |